20/20 Biolabs, Inc. (AIDX)

20/20 Biolabs Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Net Income	-3.68	-5.55	-6.39
Depreciation & Amortization	0.11	0.14	0.17
Other Operating Activities	1.63	2.81	1.74
Operating Cash Flow	-1.94	-2.6	-4.48
Capital Expenditures	0	-	-0.04
Investing Cash Flow	0	-	-0.04
Share Issuance / Repurchase	-	0.29	0
Debt Issued / Paid	-	-	-0.05
Other Financing Activities	0.88	-	-0.15
Financing Cash Flow	0.88	0.29	-0.19
Net Cash Flow	-1.07	-2.31	-4.72
Free Cash Flow	-1.94	-2.6	-4.52
Free Cash Flow Margin	-95.18%	-148.30%	-317.61%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).